219 related articles for article (PubMed ID: 35013835)
1. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
Guimarães M; Somville P; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
[TBL] [Abstract][Full Text] [Related]
2. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
Guimarães M; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
[TBL] [Abstract][Full Text] [Related]
4. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245
[TBL] [Abstract][Full Text] [Related]
5. Montelukast microsuspension with hypromellose for improved stability and oral absorption.
Lee HR; Park HJ; Park JS; Park DW; Ho MJ; Kim DY; Lee HC; Kim EJ; Song WH; Park JS; Choi YS; Kang MJ
Int J Biol Macromol; 2021 Jul; 183():1732-1742. PubMed ID: 34051251
[TBL] [Abstract][Full Text] [Related]
6. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.
Van der Vossen AC; Hanff LM; Vulto AG; Fotaki N
Br J Clin Pharmacol; 2019 Aug; 85(8):1728-1739. PubMed ID: 30964947
[TBL] [Abstract][Full Text] [Related]
7. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
8. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
9. Simulation of in vitro dissolution behavior using DDDPlus™.
Almukainzi M; Okumu A; Wei H; Löbenberg R
AAPS PharmSciTech; 2015 Feb; 16(1):217-21. PubMed ID: 25409918
[TBL] [Abstract][Full Text] [Related]
10. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product.
Chen Y; Feng T; Li Y; Du B; Weng W
Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222
[TBL] [Abstract][Full Text] [Related]
11. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
Okumu A; DiMaso M; Löbenberg R
Pharm Res; 2008 Dec; 25(12):2778-85. PubMed ID: 18560996
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
[TBL] [Abstract][Full Text] [Related]
13. Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.
Arnold DH; Van Driest SL; Reiss TF; King JC; Akers WS
J Clin Pharmacol; 2021 Mar; 61(3):360-367. PubMed ID: 32960980
[TBL] [Abstract][Full Text] [Related]
14. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
[TBL] [Abstract][Full Text] [Related]
15. Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.
Kim DW; Kim YH; Yousaf AM; Kim DS; Kwon TK; Park JH; Kim YI; Park JH; Jin SG; Kim KS; Cho KH; Li DX; Kim JO; Yong CS; Woo JS; Choi HG
Arch Pharm Res; 2016 Apr; 39(4):539-546. PubMed ID: 26983932
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.
Shawahna R; Zyoud A; Haj-Yahia A; Taya R
AAPS PharmSciTech; 2021 Mar; 22(3):84. PubMed ID: 33649887
[TBL] [Abstract][Full Text] [Related]
17. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
Karkossa F; Krueger A; Urbaniak J; Klein S
AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
[TBL] [Abstract][Full Text] [Related]
18. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
[TBL] [Abstract][Full Text] [Related]
19. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method.
Zaid AN; Abualhasan MN; Watson DG; Mousa A; Ghazal N; Bustami R
Drug Des Devel Ther; 2015; 9():5315-21. PubMed ID: 26451086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
